XERS Q1 2024 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+22.4% YoY

Gross Profit

$35M85.3% margin

Operating Income

-$14M-35.1% margin

Net Income

-$19M-46.7% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

-8.5%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$337M

Total Liabilities

$346M

Stockholders' Equity

-$9M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$33M	+22.4%
Gross Profit	$35M	$28M	+24.4%
Operating Income	-$14M	-$13M	-7.3%
Net Income	-$19M	-$17M	-12.7%

Revenue Segments

Product

$40M75%

Keveyis

$13M25%